Dexmedetomidine and Melatonin for Postoperative Sleep Disturbances and Delirium in Neurosurgical ICU: An Observational Study of 40 Patients
DOI:
https://doi.org/10.69980/ajpr.v28i5.652Keywords:
Dexmedetomidine, Melatonin, Sleep disturbances, Delirium, Neurosurgery, ICUAbstract
Background: Postoperative sleep disturbances and delirium are frequent in neurosurgical ICU patients, leading to agitation, sympathetic surges, raised intracranial pressure, and prolonged ICU stay. Pharmacological strategies remain underexplored.
Methods: This prospective observational study was conducted at SKIMS Soura Srinagar between August 2024 and July 2025. Forty postoperative neurosurgical ICU patients with intracranial tumors who developed sleep disturbances and delirium were included. Patients were managed with either low-dose dexmedetomidine infusion (0.2–0.4 μg/kg/hr, no loading dose) or oral melatonin (3–6 mg at bedtime). Primary outcomes were sleep quality and delirium resolution; secondary outcomes were adverse effects and ICU stay.
Results: Twenty patients received dexmedetomidine and twenty received melatonin. Dexmedetomidine improved nocturnal sleep continuity in 85% and resolved delirium in 90% of patients within 24 hours, but was associated with mild bradycardia in 2 patients. Melatonin improved sleep–wake rhythm in 80% and resolved delirium in 75% of patients within 48 hours, with no haemodynamic side effects. Mean ICU stay was 4.2 ± 1.1 days in the dexmedetomidine group and 4.6 ± 1.3 days in the melatonin group.
Conclusion: Both dexmedetomidine and melatonin are effective in managing postoperative sleep disturbances and delirium in neurosurgical ICU patients. Dexmedetomidine provides rapid control of agitation and sleep induction, whereas melatonin restores circadian rhythm with excellent safety.
References
1. Shehabi Y, et al. Dexmedetomidine for delirium and agitation in ICU: current evidence and future directions. Crit Care. 2021;25:322.
2. Youn S, et al. Effects of melatonin on postoperative sleep and delirium in neurosurgical patients: a randomized controlled trial. J Neurosurg Anesthesiol. 2022;34(3):247–254.
3. Kaur H, et al. Dexmedetomidine sedation in neurocritical care: clinical update. Indian J Anaesth. 2021;65(10):737–745.
4. Flannery AH, et al. Sleep and circadian rhythm disruption in critical illness: current concepts and future directions. Crit Care Med. 2022;50(1):134–144.
5. Pandharipande PP, et al. Effect of dexmedetomidine versus lorazepam on outcome in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–2653.
6. Lewis SR, et al. Dexmedetomidine for sedation in critically ill adults. Cochrane Database Syst Rev. 2018;6:CD010268.
7. Gitto E, et al. Melatonin as a treatment for sleep disturbances in critically ill patients. Eur Rev Med Pharmacol Sci. 2020;24(3):1589–1596.
8. Li CX, et al. Dexmedetomidine and postoperative delirium: a meta-analysis of randomized controlled trials. J Clin Anesth. 2021;72:110310.
9. Hanania M, et al. The role of melatonin in sleep disorders in ICU patients: a systematic review. Sleep Med Rev. 2021;57:101463.
10. Akeju O, Brown EN. Neural oscillations demonstrate that general anesthesia and sedative states are neurophysiologically distinct from sleep. Curr Opin Neurobiol. 2017;44:178–185.
11. Mahmood NA, et al. The impact of sleep disruption on ICU outcomes: mechanisms and management strategies. Intensive Care Med. 2020;46:627–640.
12. Carrasco G, et al. Dexmedetomidine versus midazolam or propofol for sedation in ICU: a systematic review and meta-analysis. Ann Intensive Care. 2017;7:82.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 American Journal of Psychiatric Rehabilitation
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License permitting all use, distribution, and reproduction in any medium, provided the work is properly cited.
